For U.S. Residents Only

CABLIVI Confidence

CABLIVI was tested in a clinical study of adults with aTTP. It included 145 people with aTTP, of whom 72 received CABLIVI with plasma exchange and immunosuppressive therapy. The other 73 people received placebo (an injection without active medicine) with plasma exchange and immunosuppressive therapy.

Both groups received either treatment with CABLIVI or placebo during daily plasma exchange therapy and for 30 days after. Some people received treatment for an additional 28 days based on their doctor’s decision. After treatment was stopped, everyone was followed by their doctor for 28 more days.

img

CABLIVI helped return platelet counts to normal significantly faster when added to PEX and immunosuppressive therapy

img

67% fewer patients relapsed while taking CABLIVI, where a drop in platelets required restarting PEX, during treatment and for 28 days after

Significantly fewer people had another episode of aTTP that required starting plasma exchange again within the full study period (while taking CABLIVI and 28 day after stopping CABLIVI) in the CABLIVI group vs the placebo group. 13% receiving CABLIVI (9 people) vs 38% receiving placebo (28 people).

img

CABLIVI is the first and only FDA-approved therapy for adults with aTTP in combination with plasma exchange and immunosuppressive therapy

img

CABLIVI treatment starts in the hospital

Learn how to take CABLIVI
img

Create a handy aTTP identification card

Get your card today
img

CABLIVI is the treatment you can trust

Learn more about CABLIVI safety
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Add
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants. CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATIONS:
What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

TTP=thrombotic thrombocytopenic purpura.